- Richard T. McKernan
- Phillip R. Chapman
- Thomas Fairfield
- Charles Farkas
- Joseph Keegan, Ph.D.
- Stephen M. McLean
- Emery Olcott
- Richard Upton
- Tracy Marshbank
Richard was Chairman of the Board of Agencourt BioScience Corporation and Agencourt Personal Genomics. Prior to his role as Chairman, Richard served as President of Packard Instrument Company and Board member of Packard BioScience Corporation and Canberra Industries. Richard has had 40 years of management experience with twenty years in the Life Sciences Industry. Richard's management experience includes engineering, operations, domestic and international sales and service, marketing and strategic planning. Richard has managed the turnarounds of five companies and led the acquisition and divestiture of over a dozen product lines, technologies and companies. In the life science field he has experience in nuclear, luminescent, and fluorescent counting and imaging equipment, micro plate robotic systems, immunoassay equipment and reagents. He was the lead presenter in a public bond offering and the initial public offering of Packard Bioscience Company stock and participated in the negotiations for the acquisition of Packard by PerkinElmer Corporation. During his career Mr. McKernan was a key participant on management teams that generated over $1.0 billion in shareholder wealth. Mr. McKernan was a long time member and past Board member of ALSSA, a prominent Life Sciences industry association. Philip R. Chapman serves as President of Venad Administrative Services Inc., a management services company. Since 1993, Mr. Chapman has been President of Adler & Company. He serves as General Partner in Euro-America II LP, a private venture capital fund, and a Managing Partner of Zenith Asset Management, a private hedge fund. He has been Chairman of Shells Seafood Restaurants Inc. since April 2002 and has been its Director since May 1997 and is Chairman of Stock Option and Compensation Committee and Member of Executive Committee. He has been a Director of Regeneration Technologies Inc. since it began operations in February 1998 and is a Member of Compensation and Audit Committees and various private companies. He holds a B.S. and an M.B.A. from Columbia University.
Thomas L. Fairfield has been chief operating officer and a director of WMI Holdings Corp. (“WMIHC”) since April 2015. Prior to joining WMIHC Mr. Fairfield held various executive officer positions with Capmark Financial Group Inc. (“Capmark”) from March 2006 through April 2015, including Executive Vice President, Chief Operating Officer and General Counsel. Mr. Fairfield has also been a member of the Board of Directors of Capmark since September 2011. From August 2013 to March 2014, Mr. Fairfield served as a director of The Cash Store Financial Services Inc. Prior to joining Capmark, Mr. Fairfield was a partner at the law firm of Reed Smith LLP from September 2005 to March 2006, a partner at Paul, Hastings, Janofsky & Walker LLP from February 2000 to August 2005 and a partner at LeBoeuf, Lamb, Greene & MacRae, LLP, from January 1991 to February 2000, where his practice focused primarily on general corporate and securities law, mergers and acquisitions, corporate finance and financial services.
Charles Farkas is a senior partner of Bain & Company. He joined the firm in 1979 and was elected to the partnership in 1985. Mr. Farkas advises chief executives and senior managers on issues critical to long-term success. He was the founder of Bain and Company’s Hospital Consulting Practice in 1985 and he has served as Chairman, Bain Canada from 1992-1994, the Global Leader of Bain & Company’s Financial Services Practice from 1995-1999, and the North American Head of Bain’s Healthcare Practice from 2004-2008.
His primary focus over the past 35 years has been healthcare. He has worked globally with 4 of the 5 leading medical technology companies, 8 of the 10 largest pharmaceutical companies, many of the leading academic medical centers, and a variety of leading healthcare providers and service companies. He also advises a number of healthcare start-up companies and private equity investors in healthcare. Mr. Farkas has extensive experience with healthcare M&A, growth strategies, productivity improvement, and merger integration.
With over 35 years consulting experience, Mr. Farkas is highly sought out by clients for his experience with issues of growth, strategy, leadership and change. He is the author of the best-selling book Maximum Leadership (1996) and numerous articles in the Harvard Business Review, Fortune, In Vivo, and other publications. In 2008 Consulting Magazine named Mr. Farkas on the Top 25 Consultants in America.
Mr. Farkas earned an MBA from Harvard Business School. He is a graduate of Princeton University where he received a Bachelor of Arts in History with honors. From 1976-1978, Mr. Farkas was ITT International Fellow in Manila, Philippines.
Mr. Farkas is a member of the Board of CONMED Corporation (CNMD, NASDAQ) where he is on the Audit Committee and CEO Search Committee. He also serves as a Corporator of Partners Healthcare and is a member of the Board of the Harvard Medical School.
Dr. Keegan has more than 30 years of experience in life science businesses. As CEO at ForteBio, Inc. he led the Series C financing which raised $25M, established product development and sales strategies that resulted in 2007-11 compounded annual revenue growth of 45% to $27M , and exited the company in 2012 through its sale to Pall Corporation for a return to investors of $160M. During his 9 year tenure as CEO at Molecular Devices Corporation, Dr. Keegan grew the company's revenues from $30M to $185M through internal growth and acquisitions. In early 2007, he oversaw its acquisition by MDS Corporation for $615M. Dr. Keegan joined MDC from Becton Dickinson and Company where he served as President of Worldwide Tissue Culture and Vice President, General Manager of Worldwide Flow Cytometry. Prior to Becton Dickinson, Dr. Keegan was Vice President of the Microscopy and Scientific Instruments Division of Leica, Inc. He currently serves on the Boards of Directors of Advanced Cell Diagnostics, Courtagen Life Sciences, Labcyte Corporation as Chairman, Optofluidics, Inc., Response Biomedical Corporation (RBM:Toronto), Seahorse Bioscience Inc., Stereotaxis, Inc. (Nasdaq: STXS), Unchained Labs, Inc., Wasatch Microfluidics, Inc., ALDA as Past Chairman and the San Francisco Opera. Dr. Keegan holds a B.A. in Chemistry from Boston University and a Ph.D. in Physical Chemistry from Stanford University.
Mr. McLean is a Partner, co-Head of the Healthcare Group, of Arsenal Capital Partners. Arsenal manages $1.6 billion of private equity capital for investments in middle market companies. Previously, Mr. McLean was a founding partner of Merrill Lynch Capital Partners, Inc. (and its successors, Stonington Partners and Arena Capital Partners), a leader in the development of the Leveraged Buyout Industry. Over the last 30 years, Mr. McLean has helped to raise and manage aggregate private equity funds of over $4 billion.
Mr. McLean has also been an active personal investor/board member of private companies in the healthcare industry at the integration of Life Sciences and Information Services. Mr. McLean helped to found and served as a director of Agencourt Bioscience Corporation and Agencourt Personal Genomics. He has previously been an investor and member of the board of directors of Packard Bioscience, Cure DM, Obagi Medical and EduNeering. Mr. McLean currently serves on the Board of Directors of the WIRB Copernicus Group, Certara, TractManager, Courtagen Life Sciences, and CentriHealth.
Mr. McLean is a founder and the Chairman of the International Biomedical Research Alliance, (the “Alliance”). The Alliance is a private sector foundation formed to support an advanced biomedical PhD program, the NIH Oxford Cambridge Scholars Program, (the “Program”). The Program was established in 2000 to accelerate the training of American and British biomedical PhD’s. It is the only academic program in the world to be an affiliate of the Rhodes scholarship.
Mr. McLean holds an M.B.A. with distinction from the Wharton School (1980) and a B.S. in Economics summa cum laude from the University of Pennsylvania (1979). He has been an occasional lecturer at Wharton for the Wharton Department of Business Ethics.
Emery Olcott graduated from Yale University with a degree in Industrial Management and he received an MBA from MIT's Sloan School of Management. Based on the acquisition of Sturrup Nuclear, a small failing electronics company, Emery founded Canberra Industries as an incubator for high tech start ups. The company evolved into a highly successful nuclear instrument company and a thriving Canberra Clinical Laboratory. The laboratory became the largest in New England and was sold to Corning. Canberra Industries served as a platform company for acquisitions including Radiation Management Company, Radiomatic Instrument Company, Nuclear Data, Tennelec as well as numerous European distributors. Canberra branched into the life science market with the acquisition of Packard Instrument Company from United Technologies. Packard had been failing to meet UTCs financial goals and was being discarded. Richard McKernan, a Canberra officer at the time, took control of Packard and refocused the organization and returned the company to healthy growth and profitability. Packard's product lines were expanded with internal development and acquisitions of Carl Creative Systems, Biosignal and others. Packard entered into a strategic marketing agreement with Agencourt Biosciences and Emery served as a member of the Board of Directors and was an early investor. Packard and Canberra were merged into Packard Bioscience and taken public in 2001. Canberra was sold to Cogema, a French nuclear conglomerate, and Packard was purchased by PerkinElmer. Over the years, Mr Olcott's activities returned close to $1 billion to shareholder's and employees.
Richard Upton was most recently the founder and President of Upton Advisors, LLC, a boutique investment bank serving middle market and emerging healthcare companies throughout the United States. Mr. Upton has been advising early stage and growth stage companies since 1992 both as a senior healthcare investment banker for Salomon Brothers and later as an independent adviser. Mr. Upton has completed engagements representing aggregate transaction values in excess of $5 billion. Mr. Upton has served on the Board of Directors of six companies and helped start four companies. He currently serves on the Boards of Courtagen Life Sciences, Inc., Castlewood Surgical, and Carmell Therapeutics, and previously served on the Board of Home Diagnostics, Inc. (NASDAQ: HDIX – acquired by Nipro Corporation). Mr. Upton is a member of the Investment Committee of the New Hampshire Charitable Foundation, and is former Chairman of The Pine Hill Waldorf School. Mr. Upton is also a founding member of Northeast Angels, an early stage angel investing group based in southern New Hampshire. Mr. Upton received his MBA degree from The Darden School at the University of Virginia and a dual BA degree in Economics and English from Amherst College.
Tracy Marshbanks is a managing director coordinating investment and research in life science technology and clean-tech/chemicals. He specializes in businesses where chemical and life science technologies are a key differentiating element. Prior to joining First Analysis in 1999, he held a number of positions with Amoco Corp. ranging from refining research and development to capital planning (first in petroleum refining and then in marketing). He earned an MBA from the University of Chicago, a doctorate in chemical engineering from Purdue University, and a bachelor's degree in chemical engineering from Colorado State University. Back to Top
*Does not include Founder Directors